✦ LIBER ✦

PAR5 COST-EFFECTIVENESS OF RITUXIMAB AS A NEW TREATMENT MODALITY FOR RHEUMATOID ARTHRITIS IN GERMANY

✍ Scribed by A Rubbert; A Kielhorn; S Schach; B Brown

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

PAR4 COST-EFFECTIVENESS ANALYSIS OF RITU

✍ D Porter; G Lewis; B Brown; A Diamantopoulos; A Kielhorn 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 65 KB

PAR7 MODELLING OF THE COST-EFFECTIVENESS

✍ S De Vita; G Giuliani; A Diamantopoulos; B Brown; A Kielhorn 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 70 KB

PAR10 COST-EFFECTIVENESS OF RITUXIMAB TH

✍ A Kielhorn; A Rubbert; D Porter; S De Vita; B Brown; M Aristides; R Aultman; F J 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 66 KB

Cost-effectiveness analysis of rituximab

✍ Sonja Merkesdal; Timm Kirchhoff; Diane Wolka; Gunter Ladinek; Adrian Kielhorn; A 📂 Article 📅 2009 🏛 Springer 🌐 French ⚖ 293 KB

PAR5 COST-EFFECTIVENESS OF ADALIMUMAB (H

✍ N Bansback; A Brennan; N Sengupta 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 45 KB

PAR6 COST-UTILITY ANALYSIS OF RITUXIMAB

✍ B Mistry; J McCormick; A Diamantopoulos; A Kielhorn 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 71 KB